Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSM Prior Auth & Step Therapy Coverage | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Prior authorization and step therapy criteria — pharmacy & specialty drugs

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists drugs subject to prior authorization and step therapy for BCBSM Medicare Plus Blue Group PPO and Prescription Blue Group PDP (2026 plan year), including coverage requirements, prerequisite therapies, age/prescriber restrictions, and durations.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior authorization and step therapy criteria — pharmacy & specialty drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required clinical documentation (e.g., diagnostic labs, prior therapy trials) because PA is required for listed drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026plan year covered
    387pages (partial)
    multipleproducts in segment
    1 YEARcommon duration

    Coverage Criteria — Product-Level Rules

    Adbry - Initial Therapy

    Covered when ALL of the following are met:

    Adbry initial coverage criteria: Patient is at least 12 years of age; diagnosis of moderate to severe atopic dermatitis; trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil; product is not used in combination with another biologic or targeted DMARD indicated for the same condition; for patients <100 kg who achieve positive clinical response after 16 weeks, dosage limited to 300 mg every 4 weeks unless clinical rationale provided.

    Coverage duration: 1 year; reauthorization requires documentation of positive clinical response.

    Prerequisite therapy requirements

    Selected product-specific prerequisite therapy/coverage rules:

    Auvelity for MDD: Requires trial of bupropion and one other generic formulary antidepressant prior to coverage.

    Coverage duration: LIFETIME.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyPrior authorization and step therapy criteria — pharmacy & specialty drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with required clinical documentation (e.g., diagnostic labs, prior therapy trials) because PA is required for listed drugs.
    SourceLink
    On This Page
    Coverage Criteria — Product-Level RulesCoding, Thresholds, and Key Numeric CriteriaProvider Actions, Prior Authorization & Documentation RequirementsStep Therapy and Required Prior TrialsContinuation / Reauthorization RequirementsActionable Highlights and Denial RisksSite of Care and Medicare Part B vs Part D ConsiderationsBackground and Policy ScopeDefinitions and Key Terms
    Brivaracetam: Requires trial of levetiracetam and one other formulary generic anticonvulsant prior to coverage.

    Coverage duration: 1 year.

    Bosulif for accelerated/blast phase Ph+ CML: Requires prior therapy as specified in product entry prior to coverage.

    Coverage duration: 1 year.

    Cimzia — Initial therapy and indication-specific prerequisites

    Cimzia covered when ALL of the following are met:

    Cimzia general: Indication is a medically‑accepted indication; product not used in combination with another biologic or targeted DMARD for the same condition; coverage duration 1 year; reauthorization requires documentation of positive clinical response.
    Rheumatoid arthritis prior therapy: For rheumatoid arthritis: diagnosis of moderately to severely active RA AND trial of two of: Enbrel, adalimumab biosimilars (adalimumab‑AATY or adalimumab‑ADBM), Rinvoq, Xeljanz/XR, Orencia.2 of list
    Psoriatic arthritis prior therapy: For psoriatic arthritis: diagnosis of active PsA AND trial of two of: Cosentyx, Enbrel, adalimumab biosimilars, Rinvoq, Skyrizi, Wezlana/Yesintek, Xeljanz/XR, Orencia, Otezla.2 of list

    Dupixent — Indication-specific coverage criteria

    Dupixent covered when ALL of the following are met (indication-dependent):

    Dupixent general: Indication is medically‑accepted; product is not used in combination with another biologic or targeted DMARD for the same condition; coverage duration 1 year; reauthorization requires documentation of positive clinical response; age and weight minimums apply for some indications.
    Atopic dermatitis prerequisites: For atopic dermatitis (patients ≥2 years): diagnosis of moderate to severe AD AND trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.1 of list

    Applies to patients ≥2 years.

    Eosinophilic asthma prerequisites: For eosinophilic asthma: diagnosis with eosinophil count ≥150 cells/µL at initiation AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of an additional controller (e.g., leukotriene modifier, LABA, or LAMA) for patients ≥12 years.eosinophils ≥150 cells/µL
    COPD add‑on prerequisites: For add‑on maintenance in COPD: diagnosis of uncontrolled moderate to severe COPD AND eosinophil count ≥300 cells/µL AND current use of and plan to continue LABA, LAMA, and inhaled corticosteroid unless contraindicated.eosinophils ≥300 cells/µL

    Cosentyx — Indication-specific coverage criteria

    Cosentyx covered when ALL of the following are met:

    Cosentyx general: Indication is medically‑accepted; product not used in combination with another biologic or targeted DMARD for the same condition; coverage duration 1 year; reauthorization requires documentation of positive clinical response.
    AS/axSpA prerequisites: For ankylosing spondylitis and non‑radiographic axial spondyloarthritis: diagnosis required AND trial of one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen); non‑radiographic axSpA also requires objective signs of inflammation.1 NSAID trial
    ERA prerequisites: For enthesitis‑related arthritis (ERA): diagnosis of active ERA AND trial of one NSAID.1 NSAID trial

    Dalfampridine — MS walking impairment

    Dalfampridine covered when ALL of the following are met:

    Dalfampridine prerequisites: Indication is multiple sclerosis walking impairment; submission of baseline timed 25‑foot walk (T25FW) prior to initiation; patient is not wheelchair‑bound and does not become wheelchair‑bound; reauthorization requires documentation of stability or improvement on T25FW.

    Coverage duration 1 year.

    Diacomit — Anticonvulsant prerequisite

    Diacomit covered when ALL of the following are met:

    Diacomit prerequisites: Coverage requires trial of two generic anticonvulsants; for seizures associated with Dravet syndrome, requires combination use with clobazam.trial of 2 anticonvulsants

    Coverage duration 1 year.

    Copiktra — Prior therapy requirement

    Copiktra covered when ALL of the following are met for relapsed/refractory CLL or SLL:

    Copiktra prerequisites: Coverage requires trial of at least two prior therapies for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).>=2 prior therapies

    Coverage duration 1 year.

    L-glutamine — Sickle cell

    L‑glutamine covered when ALL of the following are met:

    L‑glutamine prerequisites: Patient has experienced ≥2 sickle cell‑related crises in the past 12 months AND trial of or intolerance to hydroxyurea is documented.≥2 crises in 12 months

    Coverage duration 1 year.

    Eosinophilic asthma (Fasenra)

    Covered when ALL of the following are met for eosinophilic asthma:

    Eosinophilic asthma (general): Diagnosis of eosinophilic asthma; eosinophil count ≥150 cells/µL at initiation; failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA).eosinophils ≥150 cells/µL

    Reauthorization requires documentation of positive clinical response.

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    Covered when ALL of the following are met for EGPA:

    EGPA coverage: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) with history or presence of asthma AND at least two characteristic features (examples: histopathologic eosinophilic vasculitis or perivascular eosinophilic infiltration/granulomatous inflammation; neuropathy; pulmonary infiltrates; allergic rhinitis/nasal polyps; cardiomyopathy; glomerulonephritis; alveolar hemorrhage; palpable purpura; ANCA positivity).2 features required

    Reauthorization requires documentation of positive clinical response.

    Rheumatoid arthritis

    Covered when ALL of the following are met for rheumatoid arthritis:

    Rheumatoid arthritis coverage: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine).trial of one DMARD

    Cannot be used in combination with another biologic or targeted DMARD for the same condition; coverage duration 1 year.

    Sickle cell disease (L-glutamine)

    Covered when ALL of the following are met for L‑glutamine:

    L‑glutamine coverage: Patient has experienced ≥2 sickle cell‑related crises in the past 12 months AND trial of or intolerance to hydroxyurea is documented.≥2 crises in 12 months

    Coverage duration 1 year.

    Seizure disorders (Epidiolex)

    Covered when ALL of the following are met for Epidiolex:

    Epidiolex seizure indications: For Lennox‑Gastaut syndrome and tuberous sclerosis complex: trial of two generic alternatives for seizure treatment required; for Dravet syndrome: trial of two of valproic acid, clobazam, or topiramate.2 alternatives or specified agents

    Coverage duration 1 year.

    Schizophrenia (selected products)

    Covered when ALL of the following are met for schizophrenia:

    Schizophrenia coverage: Diagnosis of schizophrenia AND trial of two generic formulary atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone).trial of two agents

    Coverage duration: LIFETIME.

    Severe osteoporosis

    Covered when ALL of the following are met for specified osteoporosis agent:

    Severe osteoporosis criteria: Documentation of bone mineral density with T‑score ≤ ‑2.5 AND trial of listed agents (Jubbonti or Stoboclo) AND trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate (coverage also allowed if patient unable to be treated with these agents).T‑score ≤ -2.5

    Coverage duration: 2 years.

    Short bowel syndrome (Gattex)

    Covered when ALL of the following are met for Gattex:

    Gattex coverage: Documentation of dependence on parenteral support for ≥ 12 months.≥12 months

    Coverage duration: 1 year.

    Type 2 diabetes mellitus (GLP-1 agents)

    Covered when ALL of the following are met for GLP‑1 agonists/related agents for T2DM:

    T2DM coverage: Submission of medical records confirming diagnosis of type 2 diabetes mellitus OR laboratory evidence (A1C ≥ 6.5% OR fasting plasma glucose ≥ 126 mg/dL OR 2‑hour plasma glucose ≥ 200 mg/dL during OGTT); excluded if used solely for weight loss.diagnostic labs or records

    Coverage duration: 1 year.

    T2DM product coverage rules

    Covered when documentation and indications meet product‑specific criteria:

    T2DM product documentation: Submission of medical records confirming diagnosis of T2DM OR lab evidence (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hour PG ≥200 mg/dL) is required; exclude use for weight‑loss only.as stated

    Coverage duration: 1 year.

    Biologic and targeted DMARDs

    Covered when ALL of the following are met for indication‑specific biologic therapies:

    General biologic/targeted DMARD criteria: Diagnosis specific to the indication (e.g., moderately to severely active RA, active polyarticular JIA, active PsA, moderate‑to‑severe plaque psoriasis, active AS, Crohn's disease, UC, HS, non‑infectious uveitis). Trial of indicated prior therapy required (e.g., one DMARD for RA; NSAID for AS). Reauthorization requires documentation of positive clinical response. Product not used in combination with another biologic/targeted DMARD for same condition.as stated

    Coverage duration: typically 1 year.

    Activated PI3K delta syndrome (APDS)

    Coverage for activated PI3K delta syndrome (APDS) requires ALL of the following:

    APDS criteria: 1) Diagnosis of APDS with an associated PI3Kd mutation; 2) documented variant in PIK3CD or PIK3R1; 3) documented APDS‑related clinical manifestations such as nodal/extranodal lymphoproliferation, recurrent oto‑sino‑pulmonary infections, or organ dysfunction (e.g., lung, liver).genetic testing and clinical features required

    Cannot be used in combination with an immunosuppressive medication for the APDS indication.

    Prerequisite therapy requirements (selected)

    Coverage requires prior trial of specified therapies for certain products:

    Topical metronidazole/ oral tetracycline sequence: For indicated dermatologic conditions (e.g., ivermectin cream for rosacea): trial of topical metronidazole AND one of oral tetracycline, doxycycline, or minocycline is required.trial documented
    Kerendia (CKD/T2DM) prerequisite: For CKD associated with T2DM (or HF with LVEF ≥40% where applicable), trial of an SGLT2 inhibitor (e.g., empagliflozin or dapagliflozin) is required unless contraindicated or intolerant.trial documented or contraindication noted

    General product-level coverage

    Products in this excerpt are covered with specified prior authorization criteria and coverage durations when the listed prerequisite therapy and additional product‑specific requirements are met.

    General product‑level coverage: Coverage durations typically 1 year; prerequisite Part D drug trials required for many products as specified per product; see product‑level entries for specifics.

    Liraglutide coverage criteria

    Liraglutide-specific criteria:

    Liraglutide for T2DM: Excluded if used solely for weight loss. For ongoing treatment of type 2 diabetes mellitus, submit medical records confirming diagnosis OR laboratory evidence (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hour PG ≥200 mg/dL during OGTT).A1c ≥6.5% / FPG ≥126 mg/dL / 2‑hour PG ≥200 mg/dL

    Coverage duration 1 year.

    Breast cancer combination therapy

    Products requiring combination endocrine therapy for HR‑positive breast cancer:

    Breast cancer combination requirement: Coverage requires combination use with an aromatase inhibitor or fulvestrant as initial endocrine‑based therapy or following progression on endocrine therapy; see product entry for exact context.

    Coverage duration: 1 year.

    Mekinist (tablet) — coverage conditions

    Covered when ALL of the following are met

    Mekinist (tablet) general: Medically‑accepted indication; coverage duration 1 year; for specified indications BRAF V600E or V600K mutation detected by an FDA‑approved test is required.
    Melanoma prerequisite therapy: For unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires prior trial of vemurafenib (Zelboraf) and cobimetinib (Cotellic) used in combination; many indications require combination use with dabrafenib.
    Combination requirement: For specified indications (melanoma, NSCLC BRAF V600E, ATC, certain solid tumors, low‑grade glioma) coverage requires combination use with dabrafenib.

    Mekinist (liquid SOLR) — coverage conditions

    Covered when ALL of the following are met

    Mekinist SOLR — swallowing impairment: Patient is unable to swallow the tablet formulation.
    Mekinist SOLR — mutation and prior therapy: Same BRAF mutation requirement and prior trial of vemurafenib + cobimetinib and combination with dabrafenib requirements as for the tablet formulation.

    Coverage duration 1 year.

    Mektovi — coverage conditions

    Covered when ALL of the following are met

    Mektovi general: Medically‑accepted indication; coverage duration 1 year.
    Mektovi — melanoma prior therapy: For unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires prior trial of vemurafenib + cobimetinib used in combination.
    Mektovi — combination requirement: Coverage for melanoma and for NSCLC with BRAF V600E requires combination use with encorafenib.

    Nucala — indication-specific coverage

    Covered when ALL of the following per indication are met

    Nucala — indications: Indications include eosinophilic asthma (EA), EGPA, HES, chronic rhinosinusitis with nasal polyposis (CRSwNP), and add‑on maintenance treatment of COPD as specified.

    Coverage duration 1 year; cannot be combined with another biologic/targeted DMARD for same condition.

    Nucala — EA criteria: Diagnosis of eosinophilic asthma with eosinophil count ≥150 cells/µL at initiation AND failure to maintain adequate control after systemic corticosteroids or high‑dose ICS plus trial of one additional controller (leukotriene modifier, LABA, or LAMA) for patients ≥12 years.>=150 cells/µL
    Nucala — EGPA criteria: Diagnosis of EGPA AND at least two typical EGPA features (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity).2 features required
    Nucala — HES criteria: Diagnosis of HES AND eosinophil count ≥1000 cells/µL at initiation AND stability on HES therapy (oral corticosteroids, immunosuppressives, or cytotoxic therapy).>=1000 cells/µL
    Nucala — CRSwNP criteria: Diagnosis of CRSwNP AND recurring polyps despite prior intranasal corticosteroid therapy (e.g., fluticasone, mometasone).
    Nucala — COPD criteria: Diagnosis of uncontrolled moderate to severe COPD AND either current eosinophil ≥150 cells/µL OR eosinophil ≥300 cells/µL within past 12 months AND current use (and plan to continue) of LABA, LAMA, and inhaled corticosteroid unless contraindicated.>=150 cells/µL or historical >=300 cells/µL

    Age-restricted prior authorization (example)

    Age‑restricted prior authorization: Prior authorization applies only to patients less than 30 years of age for the specified product entry.<30 years

    Coverage duration 1 year.

    Migraine — triptan prerequisite

    Acute migraine treatment:

    Migraine acute treatment: Coverage for acute migraine headaches requires trial of at least two generic triptans (e.g., sumatriptan and rizatriptan) unless triptan therapy is contraindicated, not tolerated, or clinically inappropriate.trial of two triptans

    Coverage duration 1 year.

    Opfolda — diagnostic and prior ERT requirements

    Opfolda (Pompe disease) coverage:

    Opfolda diagnostic and prior ERT: Confirmation of diagnosis by decreased acid alpha‑glucosidase activity on serum assay and genetic testing showing a GAA mutation; presence of symptomatic manifestations (eg progressive muscle weakness, respiratory failure, frequent upper airway infections, orthopnea, sleep apnea, morning headaches); no improvement on current enzyme replacement therapy (ERT).diagnostic testing

    Coverage duration 1 year.

    Posaconazole DR — criteria

    Posaconazole DR — prophylaxis and treatment of invasive fungal infections:

    Prophylaxis eligibility: Used as prophylaxis for invasive fungal infections (Aspergillus or Candida) in high‑risk conditions (HSCT with GVHD, hematologic malignancies with prolonged neutropenia) or for secondary prophylaxis after prior fungal infection; prophylaxis also requires trial with two of: fluconazole, itraconazole, or voriconazole.trial with two azoles

    Coverage duration 6 months for prophylaxis.

    Treatment eligibility: Used as treatment for invasive fungal infections caused by Aspergillus and Candida; treatment also requires trial with two of listed azoles.trial with two azoles

    Praluent — initiation and reauth

    Praluent (alirocumab) initiation and reauthorization criteria:

    Praluent initiation: Initiation requires confirmation of HeFH/HoFH or ASCVD/primary hyperlipidemia as appropriate; LDL while on a high‑intensity statin within last 120 days must meet thresholds (≥55 mg/dL with ASCVD; >70 mg/dL without ASCVD) and at least 12 weeks of high‑intensity statin therapy unless statin intolerance documented.LDL thresholds on high‑intensity statin

    Coverage duration: 3 years for reauthorization context.

    Praluent reauthorization: Patient continues background lipid‑lowering therapy and has demonstrated LDL reduction while on Praluent.documented LDL reduction

    Pomalidomide — prior therapy requirement

    Pomalidomide coverage for multiple myeloma:

    Pomalidomide prior therapy: Requires at least two prior therapies including lenalidomide and a proteasome inhibitor, with disease progression on or within 60 days of last therapy; must be used in combination with dexamethasone.>=2 prior therapies

    Reauthorization requires continued benefit.

    Prevymis — CMV prophylaxis

    Prevymis coverage when ALL of the following are met:

    Prevymis CMV prophylaxis: Recipient is a CMV‑seropositive allogeneic HSCT recipient OR a kidney transplant recipient at high risk (donor CMV‑seropositive/recipient CMV‑seronegative D+/R-).

    Coverage duration 1 year; applies to Prevymis PACK and TABS.

    Retevmo — RET-altered cancers

    Retevmo coverage when ALL of the following are met:

    Retevmo RET alteration: Patient has locally advanced or metastatic NSCLC with RET fusion, or medullary thyroid cancer (MTC) with RET mutation, or advanced/metastatic thyroid cancer with RET fusion, or locally advanced/metastatic solid tumors with RET fusion; RET alteration detected by an FDA‑approved test. Some indications require prior therapy such as radioactive iodine for thyroid when appropriate or prior systemic therapy for RET‑fusion solid tumors.RET fusion or mutation by FDA‑approved test

    Coverage duration 1 year.

    Eltrombopag — platelet disorders

    Eltrombopag covered when ALL of the following are met:

    Eltrombopag indications: For persistent or chronic ITP: baseline platelet count <30,000/µL AND trial of corticosteroids, IVIG, or splenectomy; for thrombocytopenia with chronic hepatitis C: baseline platelet count <75,000/µL; for severe aplastic anemia: baseline platelet count <30,000/µL.baseline platelet thresholds per indication

    Coverage duration 1 year; prerequisite Part D drug required.

    NASH/MASH — fibrosis and semaglutide trial

    NASH/MASH drug coverage when ALL of the following are met:

    NASH/MASH fibrosis requirement: Diagnosis of noncirrhotic NASH or MASH with advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive assessment AND trial of semaglutide prior to authorization.fibrosis stage F2–F3

    Renewal requires no progression to cirrhosis and demonstration of response or clinical benefit as specified; coverage duration 1 year.

    Rinvoq — multiple immune-mediated indications

    Rinvoq covered when ALL of the following are met:

    Rinvoq general: Indication‑specific diagnosis (eg moderately to severely active RA, active PsA, AS, moderately to severely active UC, CD, nonradiographic axSpA, atopic dermatitis, GCA) AND required prior trials per indication (DMARDs for RA, NSAID for AS/axSpA; for several indications trial/failure or intolerance to TNF inhibitors is required); cannot be used in combination with a potent immunosuppressant (eg azathioprine, cyclosporine) or with another biologic/targeted DMARD for the same condition.as stated

    Coverage duration 1 year; reauthorization requires documentation of positive clinical response and confirmation patient is not on a potent immunosuppressant.

    Tolvaptan — liver safety and conservative therapy trial

    Tolvaptan covered when ALL of the following are met:

    Tolvaptan criteria: Documentation that the patient does not have underlying liver disease AND trial of at least two of: furosemide, demeclocycline, or fluid restriction prior to authorization.trial of ≥2 conservative measures

    Coverage duration 1 month; prerequisite Part D drug required.

    Rezurock — chronic GVHD

    Rezurock coverage when ALL of the following are met:

    Rezurock chronic GVHD: Patient is ≥12 years with chronic graft‑versus‑host disease AND trial and failure of at least two prior lines of systemic therapy.≥2 prior systemic therapy lines

    Coverage duration 1 year.

    Initial product — medically-accepted indications with specified prerequisites

    Covered when ALL of the following are met for the unnamed initial product entry:

    Initial product criteria: Documentation that the patient does not have underlying liver disease; trial of at least two of furosemide, demeclocycline, or fluid restriction; prerequisite Part D drug use as specified.trial of ≥2 measures

    Coverage duration 1 month.

    Simponi — indication-specific criteria

    Covered when ALL of the following are met for Simponi:

    Simponi — RA: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of two of: Enbrel, adalimumab‑AATY or adalimumab‑ADBM, Rinvoq, Xeljanz/XR, Orencia AND combination use with methotrexate.trial of two agents

    Reauthorization requires documentation of positive clinical response; coverage duration 1 year.

    Simponi — PsA: Diagnosis of active psoriatic arthritis AND trial of two of: Cosentyx, Enbrel, adalimumab variants, Rinvoq, Skyrizi, Wezlana/Yesintek, Xeljanz/XR, Orencia, Otezla.trial of two agents

    Reauthorization requires documentation of positive clinical response.

    Stelara — indication-specific criteria

    Covered when ALL of the following are met for Stelara (ustekinumab / Wezlana / Yesintek):

    Stelara general: Diagnosis consistent with the indicated disease (active PsA, moderate to severe plaque psoriasis, moderately to severely active Crohn's disease, or moderately to severely active UC); product not used in combination with another biologic or targeted DMARD for the same condition; reauthorization requires documentation of positive clinical response.

    Coverage duration 1 year.

    Tafinlar — mutation and combination requirements

    Covered when ALL of the following are met for Tafinlar (and liquid formulation):

    Tafinlar criteria: For unresectable or metastatic melanoma with BRAF V600E or V600K mutation requires prior trial of vemurafenib and cobimetinib used in combination; for multiple indications Tafinlar must be used in combination with trametinib; liquid form coverage requires inability to swallow capsule formulation.

    Coverage duration 1 year.

    Tagrisso — indication-specific criteria

    Covered when ALL of the following are met for Tagrisso:

    Tagrisso NSCLC EGFR criteria: Coverage for EGFR exon 19 deletion or exon 21 L858R mutation‑positive NSCLC for adjuvant therapy after resection, first‑line in metastatic disease, or first‑line in locally advanced/metastatic disease in combination with pemetrexed and platinum‑based chemotherapy; EGFR T790M‑positive NSCLC requires progression on or after EGFR TKI therapy; other specified indications per product entry.

    Coverage duration 1 year.

    Product-specific initial coverage criteria

    Covered when product‑specific conditions and any required prior/concomitant therapies or documentation are met (see each product entry).

    Talzenna: Coverage for metastatic castration‑resistant prostate cancer requires use in combination with enzalutamide.

    Coverage duration 1 year.

    Erlotinib: For NSCLC, requires concurrent treatment with first‑line/maintenance/second+ line therapy after progression following at least one prior chemotherapy regimen; pancreatic cancer requires combination with gemcitabine; prescriber must be an oncologist.

    Coverage duration 1 year.

    Bexarotene: Capsule for cutaneous T‑cell lymphoma requires refractory disease to at least one prior systemic therapy; gel requires refractory/persistent after or intolerant of other therapies; prescriber: dermatologist or oncologist.

    Coverage duration 1 year.

    Nilotinib: Adults with CML‑CP not newly diagnosed and AP Ph+ CML require prior therapy that included imatinib; pediatric Ph+ CML‑CP and CML‑AP require prior TKI therapy.

    Coverage duration 1 year.

    Tazverik: EZH2 mutation‑positive follicular lymphoma requires prior treatment with at least two systemic therapies.

    Coverage duration 1 year.

    Tetrabenazine: Not covered in hepatic impairment, active suicidality or untreated/inadequately treated depression, or with MAO inhibitors or reserpine; CYP2D6 genotype documentation required for doses >50 mg/day.

    Coverage duration 1 year.

    Thalomid: Multiple myeloma coverage requires use in combination with dexamethasone; ENL with moderate‑to‑severe neuritis requires combination therapy.

    Coverage duration 1 year.

    Tibsovo: Coverage for cholangiocarcinoma requires previous treatment.

    Coverage duration 1 year.

    Tivdak: Recurrent or metastatic cervical cancer requires disease progression on or after chemotherapy.

    Coverage duration 1 year.

    Actemra: RA coverage requires diagnosis of moderately to severely active RA and trial of two listed agents; polyarticular JIA requires trial of two listed agents; systemic JIA requires trial of NSAID, systemic glucocorticoid, or methotrexate.

    Reauthorization requires documentation of positive clinical response; coverage 1 year.

    Trodelvy: For unresectable locally advanced/metastatic TNBC requires prior use of ≥2 systemic therapies with at least one for metastatic disease; for HR+/HER2‑ requires prior endocrine therapy and ≥2 additional systemic therapies in metastatic setting.

    Coverage duration 1 year.

    Truqap: HR+/HER2‑ advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations requires progression on ≥1 endocrine‑based regimen or recurrence within 12 months of adjuvant therapy and combination use with fulvestrant.

    Coverage duration 1 year.

    Tukysa: Advanced unresectable/metastatic HER2+ breast cancer requires trial of ≥1 prior anti‑HER2 regimen and combination with trastuzumab and capecitabine; RAS WT HER2+ metastatic CRC requires prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and combination with trastuzumab.

    Coverage duration 1 year.

    Tymlos: Requires documentation of BMD T‑score ≤ ‑2.5 AND trial of Jubbonti or Stoboclo and an oral bisphosphonate (or IV if intolerant).T‑score ≤ -2.5

    Coverage duration 2 years.

    Ubrelvy: Acute migraine treatment requires trial of ≥2 generic triptans unless contraindicated or not tolerated.trial of two triptans

    Coverage duration 1 year.

    Vanflyta: For newly diagnosed AML FLT3‑ITD positive requires use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation.

    Coverage duration 1 year.

    Venclexta: Newly diagnosed AML in adults ≥75 years or with comorbidities precluding intensive therapy requires combination with azacitidine, decitabine, or low‑dose cytarabine.

    Coverage duration 1 year.

    Veozah: Moderate‑to‑severe vasomotor symptoms due to menopause requires trial, failure, contraindication or intolerance to one preferred or generic medication for VMS.

    Coverage duration 1 year.

    Verquvo: Requires NYHA class II–IV AND LVEF <45% AND either prior HF hospitalization in prior 6 months OR outpatient IV diuretic in prior 3 months; must be taken with at least two background HF therapies (beta‑blocker, ACE/ARB/ARNI, SGLT2 approved for HF, mineralocorticoid) unless contraindicated.LVEF <45%

    Coverage duration 1 year.

    Heart failure coverage criteria (product-specific)

    Covered when ALL of the following are met for the heart‑failure‑related product(s):

    Heart failure initial criteria: Diagnosis of chronic heart failure NYHA class II–IV AND left ventricular ejection fraction (LVEF) <45%.LVEF <45%
    Additional qualifying event: Either previous hospitalization for heart failure within prior 6 months OR outpatient intravenous diuretic treatment for heart failure within prior 3 months.
    Background heart failure therapy: Must be taken in combination with at least two of: (1) metoprolol succinate, carvedilol, or bisoprolol; (2) an ACE‑inhibitor or ARB or ARNI; (3) an SGLT2 inhibitor approved for heart failure; (4) a mineralocorticoid receptor antagonist, unless contraindicated or not tolerated.

    H. pylori treatment coverage

    Covered when ALL of the following are met for H. pylori therapy products:

    H. pylori diagnosis: Documentation of Helicobacter pylori infection.
    Prior therapy requirement: Trial of a guideline‑recommended generic first‑line regimen such as clarithromycin triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) OR bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole).

    PNH EVH coverage criteria

    Covered when ALL of the following are met for treatment of EVH in PNH:

    PNH EVH diagnosis: Clinically significant extravascular hemolysis (EVH) due to paroxysmal nocturnal hemoglobinuria (PNH).
    Laboratory thresholds: Hemoglobin ≤ 9.5 g/dL AND absolute reticulocyte count ≥ 120 × 10^9/L.Hgb ≤ 9.5 g/dL; retic ≥ 120 ×10^9/L
    Combination therapy: Must be used in combination with Soliris or Ultomiris only.

    Coverage duration 1 year.

    Demodex blepharitis coverage

    Covered when ALL of the following are met for demodex blepharitis product:

    Demodex blepharitis diagnosis: Confirmation of demodex blepharitis via presence of collarettes on slit‑lamp examination.

    Coverage duration 1 year.

    Xolair coverage criteria

    Covered when ALL of the following are met for Xolair by indication:

    Xolair — allergic asthma: IgE level >30 and <700 IU/mL for ages ≥12 (age‑adjusted ranges apply for younger ages) AND positive skin test or in‑vitro reactivity to a perennial aeroallergen AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA).IgE thresholds per age

    Coverage duration 1 year.

    Xolair — CSU: Diagnosis of chronic spontaneous urticaria with symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine.

    Reauthorization requires documentation of positive clinical response.

    Xolair — CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyposis with recurring polyps despite intranasal corticosteroid therapy.

    Reauthorization requires documentation of positive clinical response.

    Verzenio coverage criteria

    Covered when ALL of the following are met for Verzenio:

    Verzenio — adjuvant high‑risk EBC: Adjuvant treatment of HR‑positive, HER2‑negative, node‑positive early breast cancer at high risk of recurrence requires combination use with tamoxifen or an aromatase inhibitor.
    Verzenio — advanced/metastatic initial therapy: HR‑positive, HER2‑negative advanced or metastatic breast cancer requires combination with an aromatase inhibitor as initial endocrine‑based therapy.
    Verzenio — progression after endocrine therapy: Advanced/metastatic disease with progression following endocrine therapy requires combination use with fulvestrant.
    Verzenio — monotherapy advanced disease: Monotherapy for advanced/metastatic HR‑positive, HER2‑negative cancer with progression requires prior endocrine and chemotherapy in the metastatic setting.

    PAH prior therapy criteria

    Covered when ALL of the following are met for pulmonary arterial hypertension (Winrevair):

    PAH prior therapy: Requires a trial of both a generic PDE5 inhibitor (sildenafil or tadalafil) AND a generic endothelin receptor antagonist (bosentan or ambrisentan).

    Coverage duration 1 year.

    Xolair initial and reauthorization criteria

    Covered when ALL of the following are met (example: Xolair for CSU and CRSwNP):

    Xolair — CSU initial: Symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine.

    Reauthorization requires documentation of positive clinical response.

    Xolair — CRSwNP initial: Diagnosis of CRSwNP AND recurring disease despite intranasal corticosteroids (e.g., fluticasone, mometasone).

    Reauthorization requires documentation of positive clinical response.

    Zilbrysq (myasthenia gravis) criteria

    Covered when ALL of the following are met for Zilbrysq in myasthenia gravis:

    Zilbrysq — diagnostic confirmation: Patient is anti‑AChR antibody positive (lab record or chart notes) AND one confirmatory test: positive edrophonium test OR history of clinical response to oral cholinesterase inhibitors OR electrophysiologic evidence (RNS or SFEMG).
    Zilbrysq — prior therapy: Previous treatment courses of at least 12 weeks with one of: methotrexate, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, or tacrolimus, unless all are contraindicated or not tolerated; patient must be currently receiving and will continue a stable regimen.

    Coverage duration 1 year.

    Xpovio coverage criteria

    Coverage for select oncology agents (example: Xpovio) when ALL are met:

    Xpovio — multiple myeloma: Adult patients with multiple myeloma: failure of one prior therapy; for relapsed/refractory multiple myeloma requires trial of at least four prior therapies including failures of specified drug classes (proteasome inhibitors, immunomodulatory agents, anti‑CD38 antibody).

    Coverage duration 1 year.

    Xpovio — DLBCL: Relapsed or refractory diffuse large B‑cell lymphoma requires trial of at least two lines of systemic therapy.

    Oxcarbazepine ER criteria

    Oxcarbazepine ER TB24 coverage:

    Oxcarbazepine ER initial: Requires trial or documented intolerance to at least two generic anticonvulsants prior to approval.trial of ≥2 anticonvulsants

    Coverage duration: LIFETIME.

    Abilify products criteria

    Abilify formulations coverage:

    Abilify Asimtufii: Requires trial of oral aripiprazole prior to coverage.trial of oral aripiprazole

    Coverage duration: LIFETIME.

    Abilify Maintena: Requires trial of oral aripiprazole prior to coverage.trial of oral aripiprazole

    Coverage duration: LIFETIME.

    Oxcarbazepine ER - Initial

    Covered when ALL of the following are met:

    Oxcarbazepine ER - Initial: Requires trial or intolerance to at least two generic anticonvulsants prior to initiation.2 trials

    Coverage duration: LIFETIME.

    Desvenlafaxine / Trintellix / Exxua - Initial

    Covered when ALL of the following are met:

    Desvenlafaxine / Trintellix / Exxua initiation: Requires trial of at least two listed generic antidepressants (examples enumerated in product entry) prior to coverage.2 trials from list

    Coverage duration: LIFETIME.

    Caplyta / Rexulti / Vraylar / Zyprexa Relprevv - Initial

    Covered when ALL of the following are met:

    Atypical antipsychotics initial: Requires trial of at least one listed generic antipsychotic (examples enumerated in product entry) prior to coverage.1 trial from list

    Coverage duration: LIFETIME.

    Apidra - Initial

    Covered when ALL of the following are met:

    Apidra initiation: Requires trial or documented intolerance to NovoLog 70/30 or NovoLog prior to coverage.trial or intolerance documented

    Coverage duration: LIFETIME.

    Aristada / Aristada Initio - Initial

    Covered when ALL of the following are met:

    Aristada: Requires trial or intolerance to Abilify Maintena or oral aripiprazole prior to coverage.trial or intolerance documented

    Coverage duration: LIFETIME.

    Aristada Initio: Requires trial of oral aripiprazole prior to coverage.trial documented

    Coverage duration: LIFETIME.

    Alcohol Prep Pads / Gauze - Initial

    Covered when ALL of the following are met:

    Supplies for insulin: Coverage for alcohol prep pads or gauze requires a claim for an insulin product within the last 180 days.insulin claim within 180 days

    Coverage duration: 1 year.

    Coding, Thresholds, and Key Numeric Criteria

    Products AffectedNDC | product
    Oxcarbazepine Er TB24 300MG, 600MGProduct listed
    Products AffectedNDC | product
    Desvenlafaxine Er TB24 100MG, 50MGProduct listed
    ExxuaProduct listed
    Exxua Titration PackProduct listed
    TrintellixProduct listed
    Products AffectedNDC | product
    CaplytaProduct listed
    RexultiProduct listed
    Vraylar CAPSProduct listed
    Zyprexa RelprevvProduct listed
    Products AffectedNDC | product
    ApidraInsulin product
    Apidra SolostarInsulin product
    Products AffectedNDC | product
    AristadaLong-acting injectable aripiprazole
    Aristada InitioInitiation product for Aristada
    Products Affected - suppliesproduct
    Alcohol Prep Pads PADS 70%Supply product
    Curity Gauze Pads 2"x2" 12 PlySupply product
    Products Affected - Invega familyNDC | product
    Invega HafyeraPaliperidone palmitate long-acting injectable
    Invega SustennaPaliperidone palmitate long-acting injectable
    Invega TrinzaPaliperidone palmitate long-acting injectable
    inv-104: Eosinophil count thresholds for asthma/COPD indications
    Eosinophilic asthma (initiation)>= 150 cells/µL at initiation of treatment
    COPD add-on maintenance (current)>= 150 cells/µL current
    COPD add-on maintenance (historical)>= 300 cells/µL within past 12 months
    HES (for contrast)>= 1000 cells/µL at initiation (HES specific)
    inv-105: Weight requirement for Ebglyss (≥ 40 kg)
    Minimum weight>= 40 kilograms
    Age requirement referenceAge >= 12 years (applies with weight criterion)
    DocumentationWeight must be documented in medical record at baseline
    inv-106: Eosinophil count at initiation (≥150 cells/µL)
    Initiation eosinophil threshold>= 150 cells/µL
    Indication contextRequired for eosinophilic asthma at treatment initiation
    Related requirementsFailure to maintain control after systemic corticosteroids or high‑dose ICS plus trial of an additional controller required
    inv-107: BMD T-score threshold (≤ -2.5)
    BMD T-score threshold<= -2.5 (T-score at or below -2.5)
    Documentation requiredBone mineral density documentation required (T-score <= -2.5)
    Prerequisite therapyTrial of Jubbonti or Stoboclo and oral bisphosphonate (or IV if intolerant) typically required
    inv-108: Parenteral support duration (≥ 12 months) for Gattex
    Parenteral support duration>= 12 months of dependence on parenteral support
    DocumentationMedical record must document dependence on parenteral support for >= 12 months
    Coverage duration noteCoverage duration typically 1 year when criteria met
    inv-109: Diabetes lab thresholds (A1C, FPG, 2-hour PG)
    A1C threshold>= 6.5%
    Fasting plasma glucose (FPG)>= 126 mg/dL
    2-hour plasma glucose (OGTT)>= 200 mg/dL during OGTT
    inv-110: A1c / FPG / 2-hour PG thresholds (duplicate threshold block)
    A1C>= 6.5%
    Fasting plasma glucose (FPG)>= 126 mg/dL
    2-hour plasma glucose (OGTT)>= 200 mg/dL
    inv-111: Eosinophil count for eosinophilic asthma (>=150 cells/µL)
    Eosinophil count at initiation (EA)>= 150 cells/µL
    Required contextApplies to eosinophilic asthma at treatment start; also requires prior controller trials as specified
    Age noteCriteria described for adults and children >=12 years where applicable
    inv-112: Eosinophil count for HES (>=1000 cells/µL)
    HES eosinophil threshold>= 1000 cells/µL at initiation of treatment
    Stability requirementCoverage for HES also requires stability on HES therapy (eg oral corticosteroids, immunosuppressive, or cytotoxic therapy)
    Indication specificityThreshold specific to hypereosinophilic syndrome indication for Nucala
    inv-113: Eosinophil count for COPD indication (>=150 current or >=300 past 12 months)
    COPD current eosinophil threshold>= 150 cells/µL (current)
    COPD historical eosinophil threshold>= 300 cells/µL within past 12 months
    Concomitant therapy requirementPatient must be currently receiving and will continue LABA, LAMA, and inhaled corticosteroid unless contraindicated
    inv-114: LDL thresholds while on high-intensity statin for Praluent
    LDL threshold with ASCVD>= 55 mg/dL while on high-intensity statin within last 120 days
    LDL threshold without ASCVD> 70 mg/dL while on high-intensity statin within last 120 days
    Statin therapy requirementAt least 12 weeks of high-intensity statin unless statin intolerance documented
    inv-115: Baseline platelet count for ITP (< 30,000 / mcl)
    ITP baseline platelet count< 30,000 / mcl
    Prerequisite therapiesTrial of corticosteroids, IVIG, or splenectomy required prior to authorization
    Coverage durationTypically 1 year when criteria met
    inv-116: Baseline platelet count for thrombocytopenia with chronic hepatitis C (< 75,000 / mcl)
    Thrombocytopenia with chronic hepatitis C baseline< 75,000 / mcl
    Indication-specific noteThreshold applies for this specific thrombocytopenia indication
    Coverage durationTypically 1 year when criteria met
    inv-117: Baseline platelet count for severe aplastic anemia (< 30,000 / mcl)
    Severe aplastic anemia baseline platelet count< 30,000 / mcl
    ContextThreshold specified for severe aplastic anemia indication
    Coverage durationTypically 1 year when criteria met
    inv-118: Liver fibrosis stage for NASH/MASH (F2 to F3)
    Liver fibrosis stage requirementF2 to F3 (advanced liver fibrosis) verified by FibroScan or imaging-based noninvasive assessment
    Prerequisite therapyTrial of semaglutide required prior to authorization
    Renewal criteriaRenewal requires no progression to cirrhosis and evidence of response or clinical benefit
    inv-119: Bone mineral density (T-score) requirement
    Bone mineral density (T-score) requirement<= -2.5 (T-score at or below -2.5)
    DocumentationBMD must be documented in the medical record
    Prior therapiesTrial of listed agents (Jubbonti or Stoboclo) and an oral bisphosphonate (or IV if intolerant) required
    inv-120: Hemoglobin threshold (≤ 9.5 g/dL) for PNH EVH
    Hemoglobin threshold (PNH EVH)<= 9.5 g/dL
    ContextRequired laboratory threshold for extravascular hemolysis in PNH
    Combination therapyMust be used in combination with Soliris or Ultomiris only
    inv-121: Absolute reticulocyte count (≥ 120 × 10^9/L) for PNH EVH
    Absolute reticulocyte count threshold>= 120 × 10^9/L
    ContextRequired laboratory threshold for EVH in PNH (with Hgb <= 9.5 g/dL)
    Combination therapyTreatment must be combined with Soliris or Ultomiris
    inv-122: Left ventricular ejection fraction (LVEF) threshold (< 45%) for heart failure agents
    LVEF threshold< 45%
    Additional HF criteriaNYHA class II-IV and recent HF hospitalization within 6 months OR outpatient IV diuretic within 3 months required
    Concomitant therapyMust be taken with at least two specified HF therapies unless contraindicated
    inv-123: Insulin claim history requirement (claim in last 180 days) for supplies
    Insulin claim history requirementClaim for an insulin product in the last 180 days
    Applies toCoverage for alcohol prep pads and gauze supplies
    DocumentationClaim history must be present in pharmacy/claims records
    inv-124: Paliperidone LAI duration requirement (once-monthly x4 months OR every-3-months x1 cycle)
    Paliperidone LAI duration requirementOnce-monthly paliperidone palmitate for at least 4 months OR every-three-month paliperidone palmitate for at least one 3-month cycle
    Applies toInvega Hafyera prior authorization (maintenance LAI requirement)
    Coverage durationCoverage duration noted as lifetime when requirement met

    Provider Actions, Prior Authorization & Documentation Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for drugs listed with (PA); clinical and/or administrative criteria must be met before coverage is provided.

    Prior Authorization

    Adbry prior authorization requirements

    Adbry requests must document patient age ≥ 12 years, trial and failure of one listed topical or systemic agent, and dosing limits for responders <100 kg; coverage duration: 1 year.

    • Age at least 12 years
    • Trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil
    • Cannot be used in combination with another biologic/targeted DMARD for same condition
    • For patients <100 kg who respond at 16 weeks, dosage limited to 300 mg every 4 weeks unless rationale provided
    • Coverage duration: 1 year
    Prior Authorization

    Cimzia prior authorization and duration

    Cimzia requires prior authorization for all labeled indications, must not be combined with another biologic/targeted DMARD for the same condition, and requires indication‑specific prior trials; coverage duration: 1 year.

    • Coverage duration: 1 year
    • Cannot be used in combination with another biologic/targeted DMARD for the same condition
    • Indication‑specific prerequisite trials required (e.g., RA and PsA require trials of specified biologics/DMARDs)
    • Reauthorization requires documentation of positive clinical response
    Prior Authorization

    Dupixent PA prerequisites and 1‑year duration

    Dupixent prior authorization is required for all medically‑accepted indications; follow the indication‑specific prerequisites (diagnosis, prior therapy failures, eosinophil thresholds where applicable) and expect 1‑year coverage.

    • Cannot be used in combination with another biologic/targeted DMARD for the same condition
    • Coverage duration: 1 year
    • Atopic dermatitis: trial and failure of one of listed topical/systemic agents
    • Eosinophilic asthma: eosinophil ≥150 cells/µL at initiation and failure of controller therapy per criteria
    • COPD add‑on: eosinophil ≥300 cells/µL and concomitant LABA/LAMA/ICS
    Prior Authorization

    General PA expectations and typical 1‑year duration

    Most product prior authorizations in this list are granted for one year; PA requests must meet the product‑specific indications and any required prerequisite therapy trials.

    • Typical coverage duration: 1 year
    • PA requires documentation meeting the product‑specific criteria and prerequisite therapy trials where specified
    Documentation Required

    Reauthorization requires documented positive clinical response

    Reauthorization for many biologic and specialty agents requires documentation of a positive clinical response to the therapy to support continued coverage.

    • Submit clinical documentation demonstrating improvement or maintained benefit at reauthorization
    • Applies to multiple biologics (example: Adbry, Cimzia, Dupixent)
    Prior Authorization

    T2DM PA — confirm diagnosis or lab evidence

    Prior authorization for agents used to treat type 2 diabetes mellitus requires submission of medical records confirming the diagnosis or laboratory evidence (A1C ≥ 6.5%, FPG ≥ 126 mg/dL, or 2‑hr PG ≥ 200 mg/dL).

    • Acceptable documentation: chart notes or lab results showing A1C ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, or 2‑hour OGTT ≥ 200 mg/dL
    • Requests for GLP‑1 agents are excluded if used for weight loss only
    Prior Authorization

    Biologic PA — diagnosis and mandated prior trials

    Biologic therapy PA requests must include the diagnosis specific to the indication and documentation of mandated prior trials (for example, DMARD trial for RA or NSAID trial for AS); reauthorization requires documented clinical response.

    • Provide indication‑specific prior therapy trials as listed (e.g., one DMARD for RA; NSAID for AS)
    • Document positive clinical response for reauthorization
    Step Therapy

    Methotrexate trial required before biologic PA

    Several rheumatoid‑arthritis and related indications require a trial of methotrexate (oral tablet) or documented difficulty with oral methotrexate before PA approval; coverage duration commonly one year.

    • Document trial of methotrexate tablet or inability to use oral methotrexate
    • PA typically issued for 1 year when criteria met
    Prior Authorization

    Combination endocrine therapy required for specified breast cancer indications

    For certain HR‑positive breast cancer indications, PA requires combination endocrine therapy (aromatase inhibitor or fulvestrant) as the initial endocrine‑based regimen or after progression, with coverage typically for one year.

    • Combination use with an aromatase inhibitor or fulvestrant as specified in the product entry
    • Coverage duration: 1 year
    Prior Authorization

    NSCLC — amivantamab combination requirement

    Coverage for specified NSCLC indications requires combination use with amivantamab; confirm combination regimen in the PA request.

    • Confirm intended concurrent use with amivantamab for locally advanced or metastatic NSCLC per product criteria
    • Coverage duration: 1 year
    Prior Authorization

    RCC — pembrolizumab (and other) combination requirements

    First‑line RCC coverage requires combination with pembrolizumab; other RCC settings require specified combinations (e.g., everolimus after prior anti‑angiogenic therapy).

    • Document combination with pembrolizumab for first‑line RCC where required
    • Document prior anti‑angiogenic therapy and planned combination with everolimus where applicable
    Prior Authorization

    KRAS G12C NSCLC — prior systemic therapy required

    Lumakras (KRAS G12C) and similar agents require at least one prior systemic therapy for locally advanced or metastatic NSCLC; expect PA for 1 year.

    • Document at least one prior systemic therapy for KRAS G12C–mutated NSCLC
    • Coverage duration: 1 year
    Prior Authorization

    mCRC — prior chemo and panitumumab combination required

    For KRAS G12C–mutated metastatic colorectal cancer, PA requires prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and combination use with panitumumab as specified.

    • Document prior receipt of fluoropyrimidine, oxaliplatin, and irinotecan regimens
    • Document plan for combination with panitumumab
    Prior Authorization

    Lynparza — platinum‑based prior chemotherapy required

    Lynparza maintenance or treatment PAs require prior platinum‑based chemotherapy for BRCA/HRR indications or other specified prior therapies (e.g., AR‑directed therapy for mCRPC); coverage duration: 1 year.

    • Document prior platinum‑based chemotherapy response for ovarian maintenance
    • For mCRPC, document prior androgen receptor‑directed therapy
    • Coverage duration: 1 year
    Prior Authorization

    Mekinist — BRAF/MEK therapy rules and combination constraints

    Mekinist (trametinib) coverage follows BRAF/MEK therapy rules: monotherapy permitted only for BRAF‑inhibitor‑naïve melanoma; many indications require prior vemurafenib+cobimetinib and/or combination with dabrafenib.

    • Monotherapy only for BRAF‑inhibitor‑naïve unresectable/metastatic melanoma with BRAF V600E/V600K detected by FDA‑approved test
    • Requires trial of vemurafenib + cobimetinib used in combination
    • Many indications require combination with dabrafenib
    Prior Authorization

    Mekinist (tablet) PA — trials and 1‑year coverage

    Mekinist tablet PA: prior authorization required; coverage duration 1 year; prior trial of vemurafenib + cobimetinib and combination/dabrafenib requirements apply per indication.

    • Prior authorization required
    • Coverage duration: 1 year
    • Prior trial of vemurafenib + cobimetinib required where specified
    Prior Authorization

    Mekinist (liquid SOLR) PA when tablets not tolerated

    Mekinist SOLR (liquid) requires PA when patient cannot swallow tablets; coverage duration 1 year and same BRAF mutation and combination/prior therapy requirements as the tablet formulation.

    • Patient must be unable to swallow tablets
    • Same BRAF V600E/V600K and prior therapy/combination requirements as tablet
    • Coverage duration: 1 year
    Prior Authorization

    Mektovi PA — oncology prior trials and 1‑year duration

    Mektovi prior authorization is required; for melanoma and NSCLC with BRAF V600E/V600K mutations, prior trials of vemurafenib + cobimetinib and combination with encorafenib are required; coverage duration: 1 year.

    • Prior authorization required
    • Prior trial of vemurafenib + cobimetinib required for melanoma
    • Combination with encorafenib required for melanoma and NSCLC per product criteria
    • Coverage duration: 1 year
    Prior Authorization

    Nucala PA — eosinophil thresholds and documentation

    Nucala PAs require indication‑specific documentation including eosinophil thresholds (e.g., ≥150 cells/µL for eosinophilic asthma; ≥1000 cells/µL for HES), relevant diagnostic features, and cannot be combined with another biologic/targeted DMARD for the same condition; coverage duration: 1 year.

    • Eosinophilic asthma: eosinophils ≥150 cells/µL at initiation and failure of controller therapy per criteria
    • HES: eosinophils ≥1000 cells/µL and stability on HES therapy
    • CRSwNP, EGPA, COPD add‑on each have specified diagnostic/lab requirements
    • Cannot be used in combination with another biologic/targeted DMARD for same condition
    • Coverage duration: 1 year
    Step Therapy

    Migraine — trial of two generic triptans required

    For acute migraine therapies, prior authorization requires documentation of trial and failure of at least two generic triptans (e.g., sumatriptan and rizatriptan) unless contraindicated or not tolerated.

    • Trial of ≥2 generic triptans required prior to approval unless contraindicated or not tolerated
    • Document trials in the PA submission
    Step Therapy

    Posaconazole — step therapy: trial of two alternative azoles

    Posaconazole DR prophylaxis/treatment PAs require trials of two alternative azoles (choose two of fluconazole, itraconazole, voriconazole) before approval.

    • Prophylaxis: trial with two of fluconazole, itraconazole, or voriconazole required
    • Treatment: trial with two of the listed azoles required
    Prior Authorization

    Praluent — LDL and statin criteria for initiation

    Praluent initiation requires LDL thresholds while on a high‑intensity statin within the prior 120 days (≥55 mg/dL with ASCVD; >70 mg/dL without ASCVD) and prior statin therapy or documented statin intolerance; reauthorization requires ongoing background lipid therapy and LDL reduction.

    • Document LDL while on high‑intensity statin within last 120 days
    • Require at least 12 weeks of high‑intensity statin unless intolerant
    • Reauthorization: continued background therapy and documented LDL reduction
    • Coverage duration noted (e.g., 3 years in entry)
    Prior Authorization

    Prevymis — CMV prophylaxis eligibility and 1‑year coverage

    Prevymis PA for CMV prophylaxis covers CMV‑seropositive HSCT recipients and high‑risk kidney transplant recipients (donor + / recipient −); coverage duration: 1 year.

    • Eligible: CMV‑seropositive HSCT recipients (R+) or high‑risk kidney transplant recipients (D+/R-)
    • Coverage duration: 1 year
    Prior Authorization

    Retevmo — RET testing and indication‑specific prerequisites

    Retevmo prior authorization requires documentation of a RET fusion or RET mutation detected by an FDA‑approved test and any indication‑specific prerequisites such as prior radioactive iodine or prior systemic therapy when applicable.

    • RET alteration must be detected by an FDA‑approved test
    • Document prior RAI for thyroid cancer when appropriate or prior systemic therapy for RET‑fusion solid tumors
    • Coverage duration: 1 year
    Prior Authorization

    Rubraca — BRCA mutation and prior chemo requirements

    Rubraca maintenance coverage requires a deleterious BRCA mutation and response to platinum‑based chemotherapy; MCRPC indication requires prior androgen‑receptor‑directed therapy.

    • Document deleterious BRCA mutation for ovarian maintenance
    • Document prior platinum‑based chemotherapy response
    • For MCRPC, document prior AR‑directed therapy
    Step Therapy

    Initial conservative therapy trial required (example)

    Prior authorization for unspecified initial product (example) requires trial of at least two conservative measures (furosemide, demeclocycline, or fluid restriction) before approval; coverage duration noted as 1 month.

    • Trial of at least two of: furosemide, demeclocycline, or fluid restriction required
    • Document absence of underlying liver disease if requested
    • Coverage duration: 1 month
    Prior Authorization

    Simponi PA — trials, combination exclusion, reauthorization

    Simponi prior authorization requires trials of two specified alternative therapies depending on indication, cannot be combined with another biologic/targeted DMARD for the same condition, and reauthorization requires documented positive clinical response; coverage: 1 year.

    • Trial of two alternatives (list varies by indication)
    • Cannot be used in combination with another biologic/targeted DMARD for same condition
    • Reauthorization requires documentation of positive clinical response
    • Coverage duration: 1 year
    Prior Authorization

    Stelara PA — trials, exclusions, reauth

    Stelara prior authorization requires indication‑appropriate diagnosis, cannot be used with another biologic/targeted DMARD for the same condition, and reauthorization requires documentation of positive clinical response; coverage duration: 1 year.

    • Cannot be used in combination with another biologic/targeted DMARD for same condition
    • Reauthorization requires documented positive clinical response
    • Coverage duration: 1 year
    Prior Authorization

    Talzenna — enzalutamide combination required

    Talzenna for mCRPC requires use in combination with enzalutamide per the PA criteria; coverage duration: 1 year.

    • Document combination use with enzalutamide
    • Coverage duration: 1 year
    Prior Authorization

    Erlotinib — concurrent/combination therapy and prescriber restriction

    Erlotinib PAs require concurrent appropriate‑line systemic therapy for NSCLC and combination with gemcitabine for pancreatic cancer; prescriber must be an oncologist; coverage duration: 1 year.

    • NSCLC: concurrent first‑line/maintenance/second+ line therapy after progression following ≥1 prior chemotherapy regimen
    • Pancreatic cancer: must be used in combination with gemcitabine
    • Prescriber restriction: oncologist
    • Coverage duration: 1 year
    Prior Authorization

    Bexarotene — refractory disease requirement

    Bexarotene capsule coverage for cutaneous T‑cell lymphoma requires refractory disease to at least one prior systemic therapy; the gel form requires refractory/persistent/intolerant status to other therapies; prescriber: dermatologist or oncologist.

    • Capsule: refractory to ≥1 prior systemic therapy
    • Gel: refractory/persistent after or intolerant of other therapies
    • Prescriber restriction: dermatologist or oncologist
    • Coverage duration: 1 year
    Prior Authorization

    Nilotinib — prior TKI/imatinib therapy required

    Nilotinib coverage for CML (adult CP not newly diagnosed; accelerated phase Ph+ CML) requires prior therapy that included imatinib; pediatric Ph+ CML-CP and CML‑AP require prior TKI therapy; coverage duration: 1 year.

    • Document prior therapy including imatinib for adult CML settings
    • Pediatric patients require prior TKI trial
    • Coverage duration: 1 year
    Prior Authorization

    Tazverik — prior systemic therapies required

    Tazverik prior authorization for EZH2‑mutant follicular lymphoma requires prior treatment with at least two systemic therapies; coverage duration: 1 year.

    • Document ≥2 prior systemic therapies
    • Coverage duration: 1 year
    Prior Authorization

    Thalomid — combination therapy requirement

    Thalomid coverage for multiple myeloma requires combination use with dexamethasone; coverage for ENL with moderate‑to‑severe neuritis requires combination therapy; coverage duration: 1 year.

    • Document combination use with dexamethasone for MM
    • ENL with neuritis: part of combination therapy
    • Coverage duration: 1 year
    Prior Authorization

    Tibsovo — prior treatment required

    Tibsovo coverage for cholangiocarcinoma requires prior treatment; coverage duration: 1 year.

    • Document prior therapy for cholangiocarcinoma
    • Coverage duration: 1 year
    Prior Authorization

    Tivdak — progression after chemotherapy required

    Tivdak coverage for recurrent or metastatic cervical cancer requires disease progression on or after chemotherapy; coverage duration: 1 year.

    • Document disease progression on/after chemotherapy
    • Coverage duration: 1 year
    Prior Authorization

    Trodelvy — prior systemic therapies required for TNBC

    Trodelvy for unresectable locally advanced or metastatic triple‑negative breast cancer requires prior use of two or more systemic therapies (one for metastatic disease); coverage duration: 1 year.

    • Document prior use of ≥2 systemic therapies with ≥1 for metastatic disease
    • Coverage duration: 1 year
    Prior Authorization

    Truqap — endocrine therapy progression and fulvestrant combo

    Truqap coverage for HR+/HER2‑ advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations requires progression on at least one endocrine‑based regimen or recurrence within 12 months of adjuvant therapy and combination use with fulvestrant; coverage duration: 1 year.

    • Document progression on ≥1 endocrine regimen or recurrence within 12 months
    • Document planned combination with fulvestrant
    • Coverage duration: 1 year
    Prior Authorization

    Tukysa — prior regimens and combination requirements

    Tukysa coverage for advanced unresectable or metastatic HER2+ breast cancer requires prior trial of one or more anti‑HER2 regimens and combination with trastuzumab and capecitabine; RAS wild‑type HER2+ mCRC requires prior fluoropyrimidine/oxaliplatin/irinotecan chemotherapy and combination with trastuzumab; coverage duration: 1 year.

    • Document prior anti‑HER2 regimen(s)
    • Document planned combination with trastuzumab + capecitabine
    • For mCRC, document prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy

    Step Therapy and Required Prior Trials

    RequirementDetails
    Step therapy required where specified
    See individual product entries for specific step therapy requirements (number and class of prior agents vary by drug and indication).
    RequirementDetails
    Number and list of required prior agent trials vary by drug and indication
    Examples: RA/PsA/psoriasis agents commonly require trials of two listed alternatives; some oncology and specialty agents list indication‑specific prior therapies—see product nodes for exact lists.
    RequirementExamples / Notes
    Two generic alternatives or multiple prior systemic therapies may be required
    Epidiolex: trial of 2 generic alternatives for Lennox‑Gastaut and TSC seizures; many oncology agents (e.g., Fotivda) require two or more prior systemic therapies.
    RequirementSupported by (product examples)
    Trial of specified prior therapy is required and must be documented
    Methotrexate trial required for some biologics; products require documentation of prior DMARD or other named prior agents per product entry.
    RequirementProducts / Details
    Trial of two specified biologic/targeted DMARDs required
    Example: Kevzara and Kineret for RA indications require trials of two of listed alternatives (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia).
    RequirementDetails
    Antipsychotic prior trial required
    Lybalvi and similar atypical antipsychotic approvals require trial of at least one listed generic antipsychotic (e.g., aripiprazole, quetiapine, risperidone).
    RequirementProduct examples
    Multiple products require prior trials of specific agents or classes
    Examples include two generic triptans prior to acute migraine agents; vemurafenib + cobimetinib prior to Mekinist/Mektovi in BRAF‑mutant melanoma; other oncology combos noted per product.
    RequirementDetails / Examples
    Trials of specified prior therapies required before approval
    Acute migraine: trial of at least two generic triptans required; Posaconazole DR prophylaxis/treatment requires trial with two of fluconazole, itraconazole, or voriconazole.
    RequirementProducts / Details
    Bisphosphonate trial required prior to specified osteoporosis agents
    Jubbonti and Stoboclo require trial of an oral bisphosphonate or, if intolerant, an IV bisphosphonate; Tymlos also requires prior osteoporosis therapies and BMD documentation (T‑score ≤ -2.5).
    RequirementProducts / Details
    Semaglutide trial required prior to NASH/MASH agents
    Coverage for NASH/MASH requires diagnosis with advanced fibrosis (F2–F3) and a prior trial of semaglutide before authorization.
    RequirementDetails / Examples
    Conservative therapy trial required before tolvaptan
    Requires trial of at least two of furosemide, demeclocycline, or fluid restriction documented prior to tolvaptan authorization.
    RequirementDetails
    Many biologic agents require documented trials of specified alternatives (commonly two prior therapies)
    Simponi, Stelara, Taltz and other biologics specify trials of two listed alternative biologic/targeted agents or DMARDs prior to coverage; reauthorization generally requires documented clinical response.
    RequirementDetails / Examples
    Product-specific trials required before coverage
    Actemra, Trodelvy, many oncology and specialty products list required prior systemic therapies or combinations—see each product entry for the enumerated agents.
    RequirementDetails
    PAH step therapy — trial of PDE5 inhibitor and endothelin receptor antagonist required
    Pulmonary arterial hypertension coverage requires trial of both a generic PDE5 inhibitor (sildenafil or tadalafil) and a generic endothelin receptor antagonist (bosentan or ambrisentan) prior to approval.
    RequirementDetails
    Somatostatin analog trial required for carcinoid diarrhea
    Coverage for carcinoid syndrome diarrhea requires prior trial of somatostatin analog therapy (e.g., octreotide, lanreotide).
    RequirementDetails
    Trials of prior agents enumerated per product
    Many products (notably oncology and specialty agents) list specific prior therapies or lines of therapy required — e.g., Xpovio requires failure of one prior therapy for MM and multiple class failures for relapsed/refractory disease.
    RequirementDetails / Examples
    Antidepressant step — trial of at least 2 listed generic antidepressants required
    Desvenlafaxine/Trintellix/Exxua initiation requires documented trial of at least two generic antidepressants from the listed options prior to coverage.
    RequirementDetails / Examples
    Antipsychotic step — trial of at least one listed generic antipsychotic required
    Prior trial of one listed generic antipsychotic (e.g., aripiprazole, risperidone, quetiapine) is required before coverage of certain atypical antipsychotics (Caplyta, Rexulti, Vraylar, Zyprexa Relprevv).
    RequirementDetails / Duration
    Paliperidone LAI prior use requirement for Invega Hafyera
    Requires prior use of once‑monthly paliperidone palmitate for at least 4 months OR an every‑three‑month paliperidone palmitate cycle for at least one 3‑month cycle; coverage duration is lifetime.
    RequirementDetails / Exceptions
    SGLT2 step therapy — trial of generic dapagliflozin required
    Farxiga and Jardiance requests require prior trial of generic dapagliflozin; exception: step therapy does not apply to Jardiance when used to reduce risk of cardiovascular death in adults with T2DM and established CVD.
    Information to provideNotes
    Provide setting and intended use to determine Medicare Part B vs Part D coverage
    Submit information describing the use and setting of the drug (e.g., outpatient infusion in physician office vs pharmacy dispensed outpatient) to determine benefit processing under Medicare Part B or Part D.

    Continuation / Reauthorization Requirements

    Actionable Highlights and Denial Risks

    Denial Risk

    Denial risk if PA/ST criteria not met

    Failure to meet the listed PA or ST clinical and administrative criteria may result in denial of the request.

    • Ensure all prerequisite trials, diagnostic tests, and documentation are included with the PA submission
    Denial Risk

    Tadalafil‑nitrate drug‑drug exclusion

    Tadalafil is not covered when the patient is receiving nitrate therapy; do not submit PA for concurrent nitrate use.

    • Coverage is not provided for tadalafil in situations where patients are receiving nitrate therapy
    Denial Risk

    Dalfampridine — functional status exclusion and documentation

    Dalfampridine is excluded for use in patients who are wheelchair‑bound or who become wheelchair‑bound; baseline T25FW must be submitted prior to initiation.

    • Excluded if patient is wheelchair‑bound or becomes wheelchair‑bound
    • Submit baseline timed 25‑foot walk (T25FW) prior to initiation
    Denial Risk

    Combination biologic/targeted DMARD exclusion

    Use of a biologic or targeted DMARD in combination with another biologic/targeted DMARD indicated for the same condition is prohibited and may lead to denial.

    • Do not combine biologic/targeted DMARDs for the same indication when requesting PA
    • Absence of documentation confirming monotherapy where required may trigger denial
    Denial Risk

    Indication exclusion — weight‑loss use

    Requests for products used solely for weight‑loss purposes are excluded from coverage; clearly document the indication to avoid denial.

    • Excluded if medication is used solely for weight loss
    • Examples: liraglutide excluded if used for weight loss only
    Note
    Denial Risk

    Heart failure coverage triggers — documentation required

    Coverage for chronic heart failure therapies (e.g., Verquvo) is triggered only for NYHA class II–IV with LVEF <45% plus recent HF hospitalization or recent outpatient IV diuresis; missing these elements may preclude coverage.

    • Document NYHA II–IV and LVEF <45%
    • Provide evidence of HF hospitalization within 6 months OR outpatient IV diuretic within 3 months
    Denial Risk

    H. pylori — diagnosis and guideline regimen trial required

    H. pylori treatment coverage requires a documented diagnosis of H. pylori infection and trial of a guideline‑recommended generic first‑line regimen (clarithromycin triple or bismuth quadruple therapy); lack of documentation may cause denial.

    • Document H. pylori infection diagnosis
    • Document trial of a guideline‑recommended first‑line generic regimen (clarithromycin triple or bismuth quadruple)
    Denial Risk

    PNH EVH — lab thresholds and combination requirement

    PNH EVH treatment requires hemoglobin ≤ 9.5 g/dL and absolute reticulocyte count ≥ 120 × 10^9/L and must be used in combination with Soliris or Ultomiris; missing lab thresholds or combination use will not meet criteria.

    • Hgb ≤ 9.5 g/dL and absolute reticulocyte count ≥ 120 × 10^9/L required
    • Must be used in combination with Soliris or Ultomiris
    Denial Risk

    Demodex — slit‑lamp confirmation required

    Demodex blepharitis coverage requires confirmation via presence of collarettes on slit‑lamp exam; absence of this finding may lead to denial.

    • Provide slit‑lamp exam documentation showing collarettes
    • Lack of exam confirmation may result in coverage denial
    Denial Risk

    Reauthorization and prerequisite‑therapy documentation gaps — denial risk

    Failure to document required reauthorization information or prerequisite therapy trials (e.g., for CSU or CRSwNP) may result in denial of continued coverage.

    • Reauthorization requires documentation of positive clinical response for many biologics
    • Ensure prior therapy trials (e.g., second‑generation antihistamine for CSU; intranasal corticosteroids for CRSwNP) are documented
    Denial Risk

    MG documentation required — denial risk if missing

    For myasthenia gravis PAs, absence of required confirmatory testing (anti‑AChR antibody plus one confirmatory test) or documentation of prior immunosuppressant courses may result in noncoverage.

    • Anti‑AChR antibody positive result plus one confirmatory test required
    • Document prior courses (≥12 weeks) of listed immunosuppressants or provide contraindication/intolerance
    Denial Risk

    Oxcarbazepine ER — trial documentation required or denial

    Oxcarbazepine ER requests will be denied unless trials or intolerance to at least two generic anticonvulsants are documented.

    • Document trial or intolerance to ≥2 generic anticonvulsants
    • Coverage duration for qualifying patients: lifetime
    Denial Risk

    Antidepressant step — documentation required to avoid denial

    Desvenlafaxine/Trintellix/Exxua PAs will be denied if trials of at least two listed generic antidepressants are not documented.

    • Document trials of ≥2 listed generic antidepressants
    • Coverage duration: lifetime when criteria met
    Denial Risk

    Antipsychotic step — trial documentation required

    Antipsychotic PAs (Caplyta, Rexulti, Vraylar, Zyprexa Relprevv) require documentation of trial of at least one listed generic antipsychotic; lacking this may lead to denial.

    • Document trial of ≥1 listed generic antipsychotic
    • Coverage duration: lifetime when documented
    Billing Rule

    Insulin claim required for supplies coverage

    Coverage for alcohol prep pads/gauze requires an insulin claim within the prior 180 days; absence of an insulin claim will preclude coverage.

    • Provide claim history showing insulin fill in last 180 days
    Step Therapy

    Febuxostat — allopurinol trial/contraindication required

    Febuxostat prior authorization will be denied if trial of or documented contraindication/intolerance to allopurinol is not provided.

    • Document trial of allopurinol or provide documented contraindication/intolerance

    Site of Care and Medicare Part B vs Part D Considerations

    Note

    Medicare Part B vs Part D — provide use and setting information

    When a drug may be covered under Medicare Part B or Part D, submit information describing the intended use and site/setting to allow correct benefit determination (Part B vs Part D).

    • Provide use and setting details (e.g., physician‑administered in infusion center vs outpatient pharmacy) with the PA request

    Background and Policy Scope

    This prior authorization (PA) list reflects the recommendations of the Blues' Pharmacy and Therapeutics Committee and is intended to ensure appropriate, safe, and cost‑effective use of specialty and pharmacy drugs for Blue Cross Blue Shield of Michigan members in the 2026 plan year. As described in the policy, medications identified with (PA) or (ST) on the formulary require that clinical and/or administrative criteria be met before coverage is provided, and some products are subject to step therapy requiring documented trials of specified formulary agents prior to approval. (See the Formulary to confirm PA/ST status and the product‑specific entries for exact prerequisites and coverage durations.)

    Prior authorization decisions are based on the clinically specific criteria in this document—age and diagnosis limits, required laboratory or diagnostic confirmation, prerequisite therapies, prescriber or site‑of‑care restrictions, dosing or quantity limits, and reauthorization requirements. Coverage durations are typically 1 year for many products; other durations (e.g., lifetime, 3 months, or 1 month) are indicated on individual product pages. Reauthorization often requires documentation of a positive clinical response to continued therapy.

    Providers seeking authorization must submit the medical information specified in the product entry (for example: diagnostic test results, prior trial documentation, baseline measures such as timed walk tests or eosinophil counts, and evidence of ongoing background therapy). Failure to meet the listed PA/ST criteria (including missing prerequisite trials or required documentation) may result in denial of coverage. If a drug’s benefit determination may be Medicare Part B vs Part D–dependent, submit information describing the drug use and setting so the plan can determine appropriate processing.

    Definitions and Key Terms

    inv-286: Prior authorization (PA) definition
    Prior authorization (PA)A process where clinical and/or administrative criteria must be met before coverage is provided for specified medications.
    PurposeEnsures appropriate and cost-effective drug therapy per P&T Committee recommendations
    IdentifiersDrugs subject to PA/ST are identified in formulary with (PA) or (ST)
    inv-287: Step therapy (ST) definition
    Step therapy (ST)Requirement that members try and fail specified formulary drugs before a non-formulary or higher-cost drug is covered.
    ApplicationSome drugs require prior treatment with one or more formulary drugs (examples provided in policy)
    IdentificationDrugs subject to step therapy are identified in the formulary with (ST)
    inv-288: Reauthorization definition
    ReauthorizationRenewal of prior authorization which, for many biologics, requires documentation of positive clinical response to therapy.
    DocumentationMedical records or clinical notes showing improvement or benefit required at reauth
    Common durationCoverage durations for reauth commonly set to 1 year
    inv-289: EGPA definition
    EGPAEosinophilic granulomatosis with polyangiitis; coverage requires diagnosis of EGPA and history or presence of asthma plus at least two characteristic clinical features (e.g., eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity)
    Feature requirementTwo typical EGPA features required for coverage
    Related testingEosinophil counts and diagnostic workup per product (eg Nucala) required
    inv-290: T2DM diagnostic criteria
    T2DM diagnostic criteriaDiagnosis documented by A1C >= 6.5% OR fasting plasma glucose >= 126 mg/dL OR 2-hour plasma glucose >= 200 mg/dL on OGTT
    Documentation optionsMedical records (chart notes) or lab values acceptable for PA submission
    ExclusionAgents excluded if used solely for weight loss
    inv-292: BRAF V600E/V600K mutation definition
    BRAF V600E or V600K mutationTumor genomic alteration (BRAF V600E or V600K) detectable by an FDA‑approved test required for Mekinist coverage in specified indications
    ApplicationRequired for melanoma, NSCLC, ATC, certain solid tumors, and low-grade glioma indications
    Prerequisite therapyMekinist often requires prior or concurrent BRAF inhibitor combination therapy as specified
    inv-295: RET alteration definition
    RET alterationPresence of RET gene fusion or RET mutation as detected by an FDA‑approved test required for Retevmo coverage
    Indication examplesRET fusion in NSCLC, RET mutation in MTC, RET fusion in other solid tumors per product criteria
    Prior therapy notesSome indications require prior therapies (eg RAI for thyroid when appropriate)
    inv-296: Deleterious BRCA mutation-associated definition
    Deleterious BRCA mutation-associatedBRCA mutation associated with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer required for Rubraca maintenance coverage
    Therapy contextMaintenance coverage requires response to platinum-based chemotherapy
    TestingGenetic testing documentation required
    inv-297: FOP genetic confirmation requirement
    FOP genetic confirmationCoverage for fibrodysplasia ossificans progressiva requires genetic testing confirmation showing an ACVR1 mutation
    DocumentationGenetic test report required in medical record for PA
    Coverage noteIf genetic confirmation absent, not eligible per policy
    inv-298: Chronic heart failure criteria (NYHA II-IV, LVEF <45%)
    Chronic heart failure criteriaNYHA class II-IV with LVEF <45%
    Additional qualifying eventsRecent HF hospitalization within 6 months OR outpatient IV diuretic within prior 3 months typically required
    Concomitant therapyMust be taken with at least two specified HF therapies unless contraindicated
    inv-299: PNH EVH thresholds definition
    PNH EVH thresholdsHemoglobin <= 9.5 g/dL AND absolute reticulocyte count >= 120 × 10^9/L
    Combination therapy requirementTreatment must be used in combination with Soliris or Ultomiris only
    DocumentationLab values must be documented in medical record for PA
    inv-300: CRSwNP definition
    CRSwNPChronic rhinosinusitis with nasal polyposis; coverage requires diagnosis and recurrent disease despite intranasal corticosteroid therapy
    Prior therapyFailure of intranasal corticosteroids (eg fluticasone, mometasone) required
    ReauthorizationDocumentation of positive clinical response required for continued coverage
    inv-301: Anti-AChR antibody positive MG definition
    Anti-AChR antibody positive MGMyasthenia gravis confirmed by positive anti-acetylcholine receptor antibody testing plus one confirmatory test (edrophonium, clinical response to cholinesterase inhibitors, or electrophysiologic evidence)
    Prior therapy requirementPrevious treatment courses of at least 12 weeks with listed immunosuppressants required unless contraindicated
    DocumentationLab record and confirmatory test required in PA submission
    inv-302: Paliperidone LAI description and duration thresholds
    Paliperidone LAI descriptionOnce-a-month paliperidone palmitate extended-release injectable suspension (maintenance LAI)
    Duration thresholds for Invega HafyeraOnce-monthly for >=4 months OR every-three-month formulation for >= one 3-month cycle required prior to Invega Hafyera
    DocumentationPrior use must be documented in medical record for PA